Xilio Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
XLO$8.53-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5. Accrued Expenses
Accrued expenses consist of the following as of September 30, 2026 and December 31, 2025:
| September 30, · December 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| External research and development | $ | 3,648 | $ | 3,767 |
| Personnel-related | 4,740 | 5,733 | ||
| Professional and consulting fees | 634 | 2,156 | ||
| Other | 149 | 83 | ||
| Total accrued expenses | $ | 9,171 | $ | 11,739 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.